Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models ; volume:8 ; number:1 ; day:29 ; month:7 ; year:2020 ; pages:1-14 ; date:12.2020
Acta Neuropathologica Communications ; 8, Heft 1 (29.7.2020), 1-14, 12.2020
- Urheber
-
Kumar, Sathish
Lemere, Cynthia A.
Walter, Jochen
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-020-00959-w
- URN
-
urn:nbn:de:101:1-2020092520054337763016
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kumar, Sathish
- Lemere, Cynthia A.
- Walter, Jochen
- SpringerLink (Online service)
Ähnliche Objekte (12)
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations
The plasma peptides of Alzheimer’s disease
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin
Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations
The plasma peptides of Alzheimer’s disease
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin
Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations
The plasma peptides of Alzheimer’s disease
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin
Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome